DD297063A5 - Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie - Google Patents

Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie Download PDF

Info

Publication number
DD297063A5
DD297063A5 DD90343366A DD34336690A DD297063A5 DD 297063 A5 DD297063 A5 DD 297063A5 DD 90343366 A DD90343366 A DD 90343366A DD 34336690 A DD34336690 A DD 34336690A DD 297063 A5 DD297063 A5 DD 297063A5
Authority
DD
German Democratic Republic
Prior art keywords
atoms
alkyl
aryl
carbethoxy
carboxylic acid
Prior art date
Application number
DD90343366A
Other languages
German (de)
English (en)
Inventor
Wolfgang Linz
Bernward Schoelkens
Wolfgang Scholz
Gabriele Wiemer
Hansjoerg Urbach
Rainer Henning
Volker Teetz
Original Assignee
�����@������������������k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6386970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD297063(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by �����@������������������k�� filed Critical �����@������������������k��
Publication of DD297063A5 publication Critical patent/DD297063A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Crucibles And Fluidized-Bed Furnaces (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Element Separation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DD90343366A 1989-08-11 1990-08-09 Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie DD297063A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3926606A DE3926606A1 (de) 1989-08-11 1989-08-11 Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie

Publications (1)

Publication Number Publication Date
DD297063A5 true DD297063A5 (de) 1992-01-02

Family

ID=6386970

Family Applications (1)

Application Number Title Priority Date Filing Date
DD90343366A DD297063A5 (de) 1989-08-11 1990-08-09 Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie

Country Status (22)

Country Link
US (1) US5231083A (no)
EP (1) EP0417473B1 (no)
JP (1) JP3452199B2 (no)
KR (1) KR0185969B1 (no)
AT (1) ATE94409T1 (no)
AU (1) AU631914B2 (no)
CA (1) CA2023089C (no)
CS (1) CS277644B6 (no)
DD (1) DD297063A5 (no)
DE (2) DE3926606A1 (no)
DK (1) DK0417473T3 (no)
ES (1) ES2059931T3 (no)
FI (1) FI903936A0 (no)
HU (1) HU205008B (no)
IE (1) IE64604B1 (no)
IL (1) IL95327A (no)
NO (1) NO306979B1 (no)
NZ (1) NZ234836A (no)
PH (1) PH30831A (no)
PL (1) PL286442A1 (no)
PT (1) PT94957B (no)
ZA (1) ZA906327B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0682947T3 (da) 1994-05-19 1998-05-04 Mitsubishi Chem Corp Medikament til terapeutisk og profylaktisk behandling af sygdomme forårsaget af glatmuskelcelle-hyperplasi
SG68529A1 (en) * 1995-05-25 1999-11-16 Univ Singapore The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
CA2382549C (en) * 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CA2586547A1 (en) * 2004-11-05 2006-05-11 King Pharmaceuticals Research & Development, Inc. Stabilized individually coated ramipril particles, compositions and methods
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
DK2968304T3 (en) 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
DK3137168T3 (da) 2014-04-30 2022-03-21 Univ Columbia Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4311705A (en) * 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4381297A (en) * 1981-05-04 1983-04-26 E. R. Squibb & Sons, Inc. Substituted carbonyl phosphinyl-alkanoyl compounds
US4602002A (en) * 1983-02-07 1986-07-22 Merck & Co., Inc. N-carboxymethyl substituted lysyl and α-(ε-aminoalkyl) glycyl amino acid antihypertensive agents
US4587253A (en) * 1984-07-30 1986-05-06 Merck & Co., Inc. Bridged pyridine compounds useful as calcium channel blockers and analgesics
US4548941A (en) * 1984-07-30 1985-10-22 Merck & Co., Inc. 1,5-Methano-1H-4-benzazonine dicarboxylates, process for preparing and use as calcium blockers
US4599341A (en) * 1984-10-01 1986-07-08 Merck & Co., Inc. Substituted and bridged pyridines useful as calcium channel blockers
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
DE3705220A1 (de) * 1987-02-19 1988-09-01 Boehringer Ingelheim Kg Mittel zur behandlung von coronarerkrankungen oder organischem hirnsyndrom
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors

Also Published As

Publication number Publication date
AU6092090A (en) 1991-02-14
HUT54504A (en) 1991-03-28
ZA906327B (en) 1991-05-29
HU904966D0 (en) 1991-01-28
DK0417473T3 (da) 1993-12-13
IE64604B1 (en) 1995-08-23
HU205008B (en) 1992-03-30
ES2059931T3 (es) 1994-11-16
NO903532L (no) 1991-02-12
CA2023089C (en) 2003-01-14
DE3926606A1 (de) 1991-02-14
JPH0383957A (ja) 1991-04-09
EP0417473A1 (de) 1991-03-20
PT94957B (pt) 1997-05-28
JP3452199B2 (ja) 2003-09-29
CS277644B6 (en) 1993-03-17
KR0185969B1 (ko) 1999-05-01
US5231083A (en) 1993-07-27
PH30831A (en) 1997-10-17
CS395890A3 (en) 1992-08-12
NZ234836A (en) 1997-05-26
CA2023089A1 (en) 1991-02-12
NO903532D0 (no) 1990-08-10
PT94957A (pt) 1991-05-22
PL286442A1 (en) 1992-03-09
NO306979B1 (no) 2000-01-24
KR910004189A (ko) 1991-03-28
IL95327A (en) 1995-10-31
IL95327A0 (en) 1991-06-30
IE902910A1 (en) 1991-02-27
DE59002721D1 (de) 1993-10-21
FI903936A0 (fi) 1990-08-09
EP0417473B1 (de) 1993-09-15
AU631914B2 (en) 1992-12-10
ATE94409T1 (de) 1993-10-15

Similar Documents

Publication Publication Date Title
EP0219782B1 (de) Verwendung von Angiotensin-Converting-Enzym-Inhibitoren zur Behandlung von Atherosklerose, Thrombose und der peripheren Gefässkrankheit
US5256687A (en) Pharmaceutical composition for the treatment of high blood pressure
EP0417473B1 (de) Verfahren zur Behandlung der cardialen sowie der vasculären Hypertrophie und Hyperplasie
EP0551927A1 (de) Verfahren zur Behandlung der Herzinsuffizienz
DE3610391A1 (de) Verbindungen mit nootroper wirkung, diese enthaltende mittel und deren verwendung bei der behandlung und prophylaxe cognitiver dysfunktionen
EP0488059B1 (de) Verwendung einer Kombination aus Angiotensin-Converting-Enzyme-Hemmer und Calciumantagonist zur Behandlung einer Proteinurie
US5231080A (en) Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
US5747504A (en) Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors
DE3818245A1 (de) Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
EP0135182B1 (de) Verfahren zur Herstellung von N-alkylierten Dipeptiden und deren Estern
DE3410732A1 (de) Methode zur behandlung des glaukoms
DE3803225A1 (de) Aminosaeureamide mit psychotroper wirkung, verfahren zu ihrer herstellung, sie enthaltende mittel und deren verwendung
EP0331609A2 (de) Angiotensin-Converting-Enzym-Hemmstoffe mit psychotroper Wirkung
EP0215357A2 (de) Pharmazeutische Zubereitung zur Behandlung des Bluthochdrucks
DE3532035A1 (de) Neue n-alkylierte tripeptide, verfahren zu ihrer herstellung, sie enthaltende medikamente und deren verwendung
DE3901291A1 (de) Verbindungen mit psychotroper wirkung, diese enthaltende mittel und deren verwendung bei der behandlung und prophylaxe von stoerungen des zentralen nervensystems

Legal Events

Date Code Title Description
RPI Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act)
ASS Change of applicant or owner

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, FRANKFURT

Effective date: 20000519

IF04 In force in the year 2004

Expiry date: 20100810